Navigation Links
Drug Proves Effective in Slowing Melanomas
Date:4/15/2008

Riluzole, used to treat Lou Gehrig's disease, inhibits aggressive growth, study finds

TUESDAY, April 15 (HealthDay News) -- The drug riluzole, approved in the United States to treat amyotrophic lateral sclerosis (ALS), slows the growth of highly aggressive melanoma skin cancer, according to a new study.

A common feature of both melanoma and ALS (also called Lou Gehrig's disease) is an excess amount of the protein glutamate, a cellular growth factor or food for cells. Too much glutamate can overstimulate neurons to the point where they burn out -- a possible explanation for what happens in ALS, according to background information in the study. Overproduction of glutamate causes the growth and expansion of melanoma.

Riluzole (brand name Rilutek) inhibits the release of glutamate.

In laboratory tests using cultures of human melanoma cell lines, researchers at Rutgers University and the Cancer Institute of New Jersey found that riluzole appeared to switch off overproduction of glutamate and slow the growth rate of the melanoma cells. In tests on animals, the drug showed the same suppression of melanoma cell growth.

The researchers then started testing the drug on 11 people with late-stage (stage 3 or 4) melanoma. The patients in this phase 0 (exploratory, first-in-humans) trial received riluzole for two weeks.

"Our preliminary results show three solid positive responses in nine of the patients who had been able to complete the trial to date," Dr. James Goydos, a surgical oncologist at the Cancer Institute of New Jersey, said in a prepared statement.

Other patients in the group showed some indications of responding to the drug, and they'll be reassessed at the end of the trial.

The research was to be presented April 15 at the annual meeting of the American Association for Cancer Research, in San Diego.

The findings provide "enough data to show that we should go on to a more extensive (phase 1/2) trial," Goydos said. He expects it will begin later this year and include 50 to 100 patients with stage 4 melanoma.

"I think this drug is going to be extremely important as an adjunct to surgical treatment of stage 3 or stage 4 melanoma," Goydos said. "The challenge is to keep it from recurring, which has happened in patients on the order of 50 percent. With low toxicity likely, riluzole could potentially be given for long periods of time to slow down the metabolic process responsible for the disease's recurrence."

More information

The U.S. National Cancer Institute has more about melanoma.



-- Robert Preidt



SOURCE: Rutgers University, news release, April 15, 2008


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. FDA Approves First Anti-Psychotic for Kids
2. Nasal Anthrax Vaccine Proves Effective in Animal Study
3. FDA Approves New Roche West Nile Virus Blood Screening Test
4. Study Demonstrates Marteks Algal DHA Oil Improves Blood Triglyceride Lipid Levels
5. Exercise and yoga improves quality of life in women with early-stage breast cancer
6. Toddler Study Proves Humans Outsmart Apes
7. Enhanced PrecyseCode 2X(TM) Further Accelerates Remote Coding and Improves Cash Flow for Hospitals
8. FDA Approves Osteoporosis Drug to Cut Breast Cancer Risk
9. FDA Approves LEVAQUIN(R) Short-Course Therapy for Treatment of Complicated Urinary Tract Infections and Acute Pyelonephritis
10. FDA Approves SOMA(R) (carisoprodol) 250 mg
11. FDA Approves Expanded Label for FluMist(R) to Include Children Two to Five Years of Age
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... The company has developed a ... and regulatory authorities worldwide. From Children’s to Adults 50+, every formula has been ... standard. , These products are also: Gluten Free, Non-GMO, Vegan, Soy Free, ...
(Date:10/12/2017)... ... October 12, 2017 , ... The American College of ... Carol Friedman, PhD, FACMI, during the Opening Session of AMIA’s Annual Symposium in Washington, ... In honor of Morris F. Collen, a pioneer in the field of medical informatics, ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... system that we intend to develop to enable prevention of a major side ... severe hearing loss, especially in pediatric patients. For cisplatin, hearing loss is FDA ...
(Date:10/12/2017)... ... ... HMP , a leader in healthcare events and education, today announced that ... for ‘Best B-to-B Healthcare Website.’ Winners were announced during the Eddie & Ozzie Awards ... recognizes editorial and design excellence across a range of sectors. This year’s program included ...
(Date:10/12/2017)... ... October 12, 2017 , ... On Saturday, October 21, the Health ... Miles by Moonlight to raise money for the American Heart Association Heart Walk. Teams ... Teams will work together to keep their treadmills moving for 5 hours. Treadmills will ...
Breaking Medicine News(10 mins):
(Date:10/4/2017)... , Oct. 4, 2017  South Korean-based healthcare ... CPR training aide "cprCUBE" on Kickstarter. The device will ... during cardiac arrests with better efficiency compared to the ... offers real-time feedback on efficacy of the compression for ... campaign has a goal to raise $5,000. ...
(Date:10/2/2017)... , Oct. 2, 2017  AllianceRx Walgreens Prime, ... formed by Walgreens and pharmacy benefit manager Prime Therapeutics ... new brand, which included the unveiling of new signage ... , as well as at a few other company-owned ... new brand to patients, some of whom will begin ...
(Date:9/27/2017)... MIAMI , Sept. 27, 2017  Commended for their ... recent notable awards. Ranked as number one in the South ... ninth time in Inc. 5000 yearly list, the national specialty ... CEO, Armando Bardisa will soon be honored by ... Set to receive his award ...
Breaking Medicine Technology: